To assess the all-oral @ direct-acting antiviral ( @D ) regimen of ombitasvir , paritaprevir ( co-dosed with ritonavir -LSB- paritaprevir/r -RSB- ) , dasabuvir , and ribavirin in HCV genotype @-infected adults with HIV-@ co-infection , including patients with cirrhosis .